MZF1 and breast carcinoma: Constitutively active, N-terminally truncated and standard therapy resistant ErbB2/HER2 induces invasion of breast cancer cells through its downstream signalling network, which upon activation lead to the phosphorylation and activation of MZF1 at Ser 27.